{"classes":[{"categories":[{"measurements":[{"comment":"Dispersion was not estimable as 0 participants achieved MRD status","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Dispersion was not estimable as 0 participants achieved MRD status","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Dispersion was not estimable as 0 participants achieved MRD status","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG003","lowerLimit":"0.4","upperLimit":"57.9","value":"14.3"},{"groupId":"OG004","lowerLimit":"0.6","upperLimit":"80.6","value":"25.0"},{"comment":"Dispersion was not estimable as 0 participants achieved MRD status","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}],"title":"Achieved MRD status < 10^3 lymphoblasts"},{"categories":[{"measurements":[{"comment":"Dispersion was not estimable as 0 participants achieved MRD status","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Dispersion was not estimable as 0 participants achieved MRD status","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Dispersion was not estimable as 0 participants achieved MRD status","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG003","lowerLimit":"0.4","upperLimit":"57.9","value":"14.3"},{"groupId":"OG004","lowerLimit":"0.6","upperLimit":"80.6","value":"25.0"},{"comment":"Dispersion was not estimable as 0 participants achieved MRD status","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}],"title":"Achieved MRD status < 10^4 lymphoblasts"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"10"}],"units":"Participants"}],"description":"MRD was defined as the quantification of residual lymphoblast in the blood. Assessed by next generation sequencing (NGS).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 in combination with R3 IV for approximately 9 weeks (1-week lead-in window, 28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG000","title":"Phase 1b: Dose Escalation 1 (20 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 27 mg/m\\^2 dose in combination with R3 IV for approximately 9 weeks (1-week lead-in window, 28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG001","title":"Phase 1b: Dose Escalation 1 (20/27 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 27 mg/m\\^2 dose in combination with VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG002","title":"Phase 1b: Dose Escalation 2 (20/27 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 36 mg/m\\^2 dose in combination with VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG003","title":"Phase 1b: Dose Escalation 2 (20/36 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 45 mg/m\\^2 dose in combination VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG004","title":"Phase 1b: Dose Escalation 2 (20/45 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 56 mg/m\\^2 dose in combination VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG005","title":"Phase 1b: Dose Escalation 2 (20/56 mg/m^2)"}],"paramType":"NUMBER","populationDescription":"Phase 1b Induction SAS: All participants who received any amount of the study treatment regimen during the induction period and had available data.","reportingStatus":"POSTED","timeFrame":"Up to approximately Day 29 of Induction Cycle (28-days cycle, assessment on Day29)","title":"Phase 1b: Percentage of Participants Achieving Minimal Residual Disease (MRD) Status of <10-³ and <10-⁴ Lymphoblasts at the End of Induction Cycle","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}